Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 3/20 | 0.44 |
| ▸ | ACACB | O00763 | 10/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.42 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12049588 | 0.88 | PDE9A (0.45) | PDE9AACACBLIPGTEAD1 | |
| SCHEMBL20205883 | 0.83 | PDE9A (0.41) | PDE9AACACBLIPG | |
| SCHEMBL20147887 | 0.81 | PDE9A (0.43) | PDE9AACACB | |
| SCHEMBL10850371 | 0.80 | PDE9A (0.46) | PDE9AACACB | |
| SCHEMBL12050034 | 0.79 | LIPG (0.45) | ACACBLIPGTEAD1FPR2PROKR1 | |
| SCHEMBL1741828 | 0.77 | ACHE (0.48) | — | |
| SCHEMBL12026509 | 0.76 | SLC6A4 (0.44) | PDE9AACACBLIPGTEAD1FPR2 | |
| SCHEMBL12026424 | 0.76 | HRH3 (0.61) | — | |
| SCHEMBL29090107 | 0.73 | TEAD1 (0.59) | TEAD1FPR2PROKR1LIPENAAA | |
| SCHEMBL9596492 | 0.72 | ACACB (0.50) | ACACBLIPGTEAD1LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | PDE9A 1154/4885ACACB 4835/4885LIPG 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.